none 10.31254/phyto.2024.13211 BioMed Research Publishers BioMed Research Publishers 16195 160629333 316921 20240512122131292 10.31254 2024-05-12T16:21:45Z 2024-05-12T16:21:38Z 1 The Journal of Phytopharmacology J Phytopharmacol 2320480X 10.31254/phyto https://www.phytopharmajournal.com/ 4 30 2024 13 2 Anju Verma https://orcid.org/0000-0002-5775-8563 Rajani Srivastava https://orcid.org/0000-0002-2807-9123 Pankaj Kumar Sonar https://orcid.org/0000-0002-6447-0947 Ramprakash Yadav https://orcid.org/0000-0001-5199-2917 Rosa alba L. is a perennial flowering shrub belonging to the Rosaceae family. Diabetes is treated in Assam, India, with a decoction of its flower. But to date, there is no scientific evidence for its antidiabetic potential. Therefore, in addition to toxicity investigations, the current study aimed to determine its antidiabetic potential to support conventional claims. In-silico toxicity profiling for the phytoconstituents of the plant was predicted as non-toxic, non-mutagenic, and non-carcinogenic in mice and rats. The Total phenolic and total flavonoid contents were determined and found to be higher in the ethanolic extract than in the aqueous extract of the flower. Antidiabetic activity of orally administered aqueous and alcoholic extracts (200 mg/kg body weight) was evaluated against the high-fat diet fed with a low dose of streptozotocin-induced diabetic rats. Treatment of these extracts significantly (p<0.001) reduced the blood glucose level and lipid profile in induced-diabetic rats without affecting their liver and kidney functions. It was also shown that the liver and pancreatic tissues of animals treated with extracts had enhanced histopathologic architecture. The findings of the study revealed that the flowers of R. alba are a safe herbal remedy for controlling diabetes. 4 30 2024 167 176 1 10.31254/biomed-crossmark-policy www.biomedresearch.org false 10.31254/phyto.2024.13211 https://www.phytopharmajournal.com/assets/pdf_files/Vol13_Issue2_11.pdf